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Hyaluronidase-1 expression is not a predictor of biochemical
recurrence in radical prostatectomy specimens
Bayram GÜNER1, Sıdıka Şeyma ÖZKANLI2, Turhan ÇAŞKURLU3, Asıf YILDIRIM3,
Mehmet Cenk GÜRBÜZ3, Itır Ebru ZEMHERİ2

Aim: The purposes of this study were to evaluate the rate of biochemical recurrence among patients who underwent
radical prostatectomy due to localized prostate cancer, assess the risk factors of biochemical recurrence, and investigate
its relation with hyaluronidase-1 (HYAL-1).
Materials and methods: We retrospectively evaluated the data of 112 patients who underwent radical retropubic
prostatectomy. HYAL-1 expression was evaluated immunohistochemically and staining was graded as mild, moderate,
and severe. Two blinded pathologists evaluated the specimens. The relation among preoperative pathologic findings that
were detected in transrectal ultrasound (TRUS) guided biopsy, specimens of radical prostatectomy in the final stage,
and biochemical recurrence rate were also evaluated. Mean follow-up time was 59.8 months (range: 20 to 92 months).
Results: Tumor recurrence was detected in 29 patients. There was no relation between HYAL-1 expression and
recurrence. In multivariate analysis, the percentage of tumors detected in TRUS biopsy specimens, positive surgical
margin, capsular involvement, and seminal vesicle invasion detected in the final pathology were correlated with
recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of HYAL-1 expression
were respectively 38%, 63%, 30%, and 71%.
Conclusion: HYAL-1 expression was not found to be predictive for recurrence. Further molecular markers and genetic
studies are necessary to predict the biochemical recurrence after radical prostatectomy.
Key words: Prostate, prostate cancer, recurrence, hyaluronic acid

Introduction
There has been rapid development regarding
the treatment for men with localized prostate
cancer in recent years. Surveillance, radical
prostatectomy (RP), external beam radiotherapy,
and brachytherapy are used to manage localized
prostate cancer.
There was a randomized controlled trial in
Sweden. In that trial, the results of the Scandinavian
Prostate Cancer Group 4 suggested that RP may
improve overall survival if the tumor is detected at
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an early stage (1). However, biochemical recurrence
(BCR) was detected in 25% of all patients who
underwent RP for localized prostate cancer during
follow-up (2,3).
Hyaluronic acid (HA) is a glycosaminoglycan
composed of repeating D-glucuronic acid and
N-acetyl-D glucosamine units. Six HA genes were
identified in human tissues. HA regulates several
cellular functions and molecular mechanisms,
including tumor adhesion, migration, and
proliferation. HA level is high in several tumors
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such as breast, colon, bladder, lung, ovary, and,
recently, prostate (4-10). Increased expression of HA
is associated with proliferation and progression of
breast, colon, and ovarian tumors (4,5,10).
The aims of our study were to identify a profile
for hyaluronidase-1 (HYAL-1) expression in RP
specimens and to correlate it with BCR and other
classical prognostic factors.
Material and methods
We analyzed 112 RP specimens of patients with
clinical localized prostate cancer who underwent
RP between the years 2004 and 2009. This study
was approved by the İstanbul Göztepe Research and
Training Hospital review board (Date: 21.04.2010,
Number: B.10.4.ism.0.4.34.59.21. / 050.01.03).
Computed tomography and bone scintigraphy
were conducted when the prostate-specific antigen
(PSA) level was over 10 ng/dL preoperatively. Partin
and Kattan nomograms were calculated for all the
patients and lymphadenectomy was performed only
when the probability was over 10%. None of the
patients received neoadjuvant or adjuvant androgen
deprivation therapy or adjuvant radiotherapy or
chemotherapy until BCR occurred. All but 12
tissue blocks from 112 patients were analyzed. The
remaining tissue blocks from 12 patients could not
be evaluated due to tissue loss during specimen
staining. Each specimen was evaluated by 2 blinded
and experienced pathologists unaware of the patients.
BCR was defined as the case of PSA being 0.2 ng/dL or
greater in 2 successive measurements after RP. It was
found that 29 of 100 patients experienced BCR after
RP and 71 were recurrence-free. We checked PSA,
digital rectal examinations, and blood parameters (if
necessary) every 3 months during follow-up.

approximately 90 min using diluted 1:150 HYAL-1
IgG binding protein purified rabbit nasal cartilage.
After incubation with primary reagents, the slides
were incubated with Ultra Tek antipolyvalent
biotinylated antibody (ScyTek Laboratories) as the
secondary antibody for 15 min. After rehydration,
Ultra Tek HRP (ScyTek Laboratories) was added
to the specimens. After rehydration with PBS, the
AEC chromogen system (AEC substrate kit, ScyTek
Laboratories) was added to the specimens. Slides were
counterstained with hematoxylin. All prostatectomy
slides were stained twice and scored independently
to determine staining reproducibility.
Slide grading
Two blinded pathologists independently evaluated
all slides in a blinded fashion. Tumor-associated
stroma and tumor cells were graded for HYAL1 staining in each slide. Staining was observed for
all slides. The intensity of staining of HYAL-1 was
graded as 0 (no staining), 1, 2, and 3 for each slide
(Figure). The overall staining grade for each slide
was assigned based on the staining intensity of the
tumor tissue in the specimen, and the average of the
scores of the 2 readers was accepted as the specimen
score. However, if 50% of the tumor tissue showed
grade 1 and the other 50% showed grade 3 staining,
the overall staining grade was assigned to be 2. On
the other hand, if 50% of the tumor showed grade
2 and the remaining showed grade 3 staining, the
overall staining was assigned as 3. The staining scale
was then subcategorized into low and high grades.
Grade 2 and grade 3 staining represented high grade
staining and the others were defined as low grade
staining. The readers agreed with each other 90% of
the time. Any discrepancy about the grading of slides
was resolved by the 2 readers.

Immunohistochemistry

Statistical analysis

Sections of 3 μm were taken from selected paraffin
blocks that were previously coated with poly-L-lysine.
Specimen slides were then deparaffinized with xylene
for 10 min and rehydrated. Hydrogen peroxide,
phosphate buffered saline (PBS), and Ultra V block
nonspecific blocking reagent (ScyTek Laboratories,
USA) were applied as the antigen retrieval solution.
Rabbit HYAL-1 antibody (Atlas Antibodies,
Sweden) was then localized at room temperature for

Statistical analysis was done with NCSS 2007
(version 07.1.20) software. Independent t-tests and
chi-square tests were used to compare qualitative
data. Cox regression and Kaplan-Meier analysis
were used to determine the effects of recurrence and
survival rate, respectively. Log rank analysis was used
to determine the affecting factors of recurrence and
its relation with HYAL-1. The statistical significance
level was accepted as 0.05.
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HYAL-1 staining 0

HYAL-1 staining 1

HYAL-1 staining 2

HYAL-1 staining 3

Figure. Examples of staining results for HYAL-1 scores of 0, 1, 2, and 3.

Results
Preoperative mean PSA level was 11.7 ng/dL (ranging
from 1.4 to 33) and the mean follow-up time was
59.8 months (ranging from 20 to 92). Mean time to
recurrence was 45.7 months (ranging from 36 to 92)
(Table 1). Lymphadenectomy was performed in 8
patients based on Partin and Kattan nomograms.
The median age was 66.5 years (ranging from 51
to 72). Twenty-nine of all patients had BCR. Four
patients died due to prostate cancer during the
follow-up period. The HYAL-1 scores of the patients
who died were 1 in 2 patients and 3 in the remaining
2 patients. Among the surviving patients, 7 had grade
1 scores, 37 had grade 2 scores, and 56 had grade 3
scores for HYAL-1.
Sensitivity, specificity, positive predictive value,
and negative predictive value to predict BCR for
HYAL-1 were 38%, 63%, 30%, and 71%, respectively.
In a multivariate analysis that included clinical (age,
preoperative PSA, and clinical stage) and pathological
(Gleason sum, extraprostatic extension, capsule
involvement, seminal vesicle invasion, lymph node
involvement, and surgical margin status) parameters
and HYAL-1 staining scores, the preoperative PSA
level, clinical stage, Gleason score and primary
Gleason pattern on biopsy, percentage of tumor on
1022

biopsy, Gleason score on RP, primary and secondary
Gleason patterns on RP, positive surgical margin,
capsule involvement, extraprostatic expansion, and
seminal vesicle invasion were found to be significant
predictors of BCR (Tables 2 and 3).
Only the preoperative PSA level was significant
for recurrence in subgroup analysis including
extraprostatic expansion, preoperative PSA, and
HYAL-1 staining (Table 4).
We performed Cox proportional hazards analysis
to determine clinical and pathological parameters
to predict BCR. Gleason score, primary pattern on
biopsy, preoperative PSA, percentage of tumor on
biopsy, final specimen Gleason score, and primary
and secondary Gleason pattern on RP were found
statistically significant for recurrence (Tables 2 and
3).
Recurrence-free survival rates were 82.2%, 68.6%,
and 68.6% for years 1, 5, and 8, respectively. There
was no statistically significant difference between
survival rates of cT1 and cT2. Median survival rate
was not different between patients with and without
BCR (Table 5).
HYAL-1 staining was not found to be related to
overall, disease-free, and recurrence-free survival
rates.
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Table 1. Patient characteristics.

Clinical stage

Evidence recurrence

Surgical margin

RP Gleason score

Capsule involvement

Extraprostatic expansion

Seminal vesicle invasion

Lymph node involvement

Progression

HYAL-1

n

%

cT1

65

65

cT2

35

35

Positive

29

29

Negative

71

71

Negative

75

75

Positive

25

25

<7

74

74

≥7

26

26

Negative

65

65

Positive

35

35

Negative

84

84

Positive

16

16

Negative

90

90

Positive

10

10

Negative

99

99

Positive

1

1

Progression (-)

97

97

Progression (+)

3

3

Low grade

62

62

High grade

38

38

Table 2. Factors related to biochemical recurrence.
BCR (-)

BCR (+)

P-value

Age (years)

66.3 ± 6.04

67.1 ± 5.77

0.540

Preoperative PSA (ng/dL)

9.18 ± 9.70

18.16 ± 15.53

0.001

Gleason score on biopsy

5.65 ± 0.97

6.17 ± 1.20

0.024

Primary pattern on biopsy

2.75 ± 0.55

3.07 ± 0.70

0.017

2.9 ± 0.57

3.1 ± 0.72

0.139

Percentage core of tumor on biopsy

0.24 ± 0.14

0.39 ± 0.23

0.0001

Gleason score on RP

5.69 ± 1.01

6.76 ± 1.35

0.0001

Primary Gleason pattern on RP

2.75 ± 0.53

3.31 ± 0.76

0.0001

Secondary Gleason pattern on RP

2.94 ± 0.63

3.59 ± 1.24

0.001

58.34 ± 21.95

63.48 ± 21.62

0.288

Secondary pattern on biopsy

Duration of follow-up (months)

1023

Hyaluronidase-1 expression and biochemical recurrence

Table 3. Hazard ratio of related factors to biochemical recurrence.
BCR (-)
T1

53

81.50%

BCR (+)
12

OR (95% CI)

18.50%

4.17

Clinical stage

P = 0.002
T2

18

51.40%

17

48.60%

Negative

58

81.70%

17

58.60%

1.67-10.38
3.15

Surgical margin

P = 0.016
Positive

13

18.30%

12

41.40%

<7

59

83.1%

15

51.7%

1.21-8.17
4.58

Gleason sum

P = 0.002
≥7

12

16.9%

14

48.3%

Negative

54

76.10%

11

37.90%

1.76-11.95
5.20

Capsule involvement

P = 0.0001
Positive

17

23.90%

18

62.10%

Negative

67

94.40%

17

58.60%

2.06-13.14
11.82

Extraprostatic expansion

P = 0.0001
Positive

4

5.60%

12

41.40%

Negative

69

97.20%

21

72.40%

3.38-41.30
13.14

Seminal vesicle invasion

P = 0.0001
Positive

2

2.80%

8

27.60%

Negative

45

63.38%

18

62.1%

2.59-66.75
1.05

HYAL-1

P = 0.902
Positive

26

36.62%

11

37.9%

0.43-2.58

Table 4. Subgroup analysis of factors related with BCR.
95.0% CI
P

HR
Lower

Upper

Preoperative PSA

0.045

2.52

0.99

6.44

Extraprostatic expansion

0.021

1.15

0.70

2.33

HYAL-1

0.053

1.02

1.00

1.04

Table 5. Survival rates of all patients.
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Overall survival

Disease-free survival

Year 1

0.989 ± 0.011

0.989 ± 0.011

Year 2

0.989 ± 0.011

0.989 ± 0.011

Year 5

0.974 ± 0.019

0.970 ± 0.022

Year 8

0.936 ± 0.032

0.970 ± 0.022
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Discussion
Tumor cell penetration through the basement
membrane is an important component of tumor
progression. Disruption of basement membrane
integrity by hyaluronidase involves a complex
sequence of cellular and biochemical events.
HA is an important component of the extracellular
matrix (ECM), particularly in rapidly proliferating
tissues (11). HYAL-1 and HYAL-2 are the major
hyaluronidases in human tissues (12,13). HA performs
several functions, such as supporting cartilage integrity
and maintaining tissue hydration and osmotic balance
in normal physiology (14,15). Currently, there is much
evidence for the role of HA in tumor invasion and
metastasis. HA is elevated in various tumors including
bladder, breast, colon, prostate, lung, endometrial,
and ovary (4-10,16). The localization of HA is in
either tumor-associated stroma or tumor cells (47,10,17). Increased expression of HA is associated
with malignant progression in several tumors such
as breast, colon, and ovarian tumors (5,6,9,10,14). In
these tumors, stimulation of independent growth and
proliferation of tumor cells may be encouraged with HA
(18,19). Moreover, HA may support tumor metastasis
by promoting tumor cell proliferation and may also
protect against immune surveillance (20-28). Increased
hyaluronidase may facilitate ECM degradation and its
action may also promote tumor angiogenesis. HYAL1 is the major hyaluronidase expressed in bladder and
prostate cancer tissues (17,25-27).
The aim of our study was to examine the effects
of HYAL-1 expression, whose relation with other
tumors had been revealed, on the prognosis and
progression of prostate cancer. Current nomograms
that are used to predict prognosis are not useful.
This is why the addition of molecular markers due
to heterogeneity of cancer in the nomograms, which
consist of clinical and pathological parameters, may
result in better prediction. Whether HYAL-1 might
be among these molecular markers was one of the
starting questions of this study.
In 2009, Gomez et al. reported the relation
between BCR and HYAL-1 staining in transrectal
ultrasound (TRUS) biopsy specimens. In addition,
a software program was used for HYAL-1 staining
and evaluation of specimens was performed by 3
pathologists. The BCR cut-off level was 0.4 ng/dL

and the median follow-up period was 103 months
(28). Furthermore, HYAL-1 staining was statistically
significant in predicting recurrence in univariate and
multivariate analysis of RP specimens. Posey et al.
and Ekici et al. reported the prognostic potential of
histological markers for predicting BCR in prostate
cancer patients, such as HA, HYAL-1, CD44v6, and
microvessel density (29,30). The prognostic value of
each following item was less than that of the Gleason
score: microvessel density, N-acetyltransferase 2
gene polymorphism, Ki-67, p53, p27, P21, bcl-2,
PTEN mutation, Pim-1 kinase, EZH2, Bax, DNA
ploidy, methylation of the GSTP1 gene, HER-2/
neu, E-cadherin, CD44, retinoblastoma proteins,
apoptotic index, androgen receptor status, acid
phosphates, and IGF-1 expression (31-33). Although
HYAL-1 is an important prognostic factor for colon,
breast, endometrial, and bladder cancer, there
are not enough data about prostate cancer. While
HYAL-1 expression was a significant prognostic
factor for recurrence in prostate cancer patients
in the abovementioned study, our results did not
confirm this. HYAL-1 expression was not significant
in predicting BCR. Percentage of tumor on biopsy
cores, positive surgical margin, clinical stage, final
specimen Gleason sum of ≥7, seminal vesicle
invasion, capsular penetration, and extraprostatic
expansion were the factors that were related to
BCR in multivariate analysis in the present study.
We think that the minor differences of staining and
grading methods, difference of secondary antibodies,
and number of pathologists do not explain this
discrepancy. However, selection of a PSA cut-off
value of 0.2 ng/dL as BCR instead of 0.4 ng/dL, a
relatively shorter follow-up period, and a smaller
number of patients with Gleason scores of ≥8 in
addition to the heterogenic nature of prostate cancer
may have had an impact on our results.
HYAL-1 expression is not predictive of BCR in
patients with prostate cancer and did not contribute
to the use of contemporary clinical and pathologic
parameters (preoperative PSA, TRUS biopsy Gleason
sum and primary Gleason pattern, percentage of
tumor core in biopsy, Gleason sum for RP, and
primary and secondary Gleason grade) in predicting
BCR. Apparently, additional molecular markers
are required to improve our understanding of the
prognosis and nature of prostate cancer.
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